FDA orders warnings on GLP-1 drugs over rare blindness risk

· Health · United States

The US Food and Drug Administration said Tuesday that makers of GLP-1 drugs used for weight loss and diabetes, including Ozempic, Wegovy and Zepbound, must add warnings to their labels about a rare eye condition known as NAION that can lead to blindness. The agency said it found evidence of a potential increased risk of the condition linked to the drugs, which have become blockbuster treatments for obesity. Millions of people worldwide now use the medicines. The label change means patients and doctors will be formally alerted to the risk, and the drugs' makers must update their prescribing information.

Why it matters：GLP-1 drugs are used by millions, so a new safety warning affects prescribing worldwide and could shift patient demand.

Key points

  • Warning covers NAION, a rare condition that can cause blindness.
  • Labels must be updated for Ozempic, Wegovy, Zepbound and similar drugs.
  • The FDA said it found evidence of a potential increased risk.

Sources (original reporting)

More stories from this day